Moreover, CTX-8573/4,419 targets BCMA and NKp30 and promotes the lysis of NK against myeloma cells and exhibits potent antitumor efficacy in vitro and in vivo, with a broad therapeutic window (Draghi et al., 2019; Watkins-Yoon et al., 2019). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.